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Domestic Production of Anti-TB Drugs in Occupied Japan 




The purpose of this paper is to explore the reason why occupied Japan could halve tuberculosis (TB) mortality rate and improve its public health. 
Specifically, this paper examines the circumstances and history of the Japanese pharmaceutical industry, which attained to domestically produce 
higher-quality, larger-volume anti-TB drugs at a lower cost, with the intention of GHQ / SCAP / PHW. In 1945, Japan's public health seemed to 
be devastated. TB in Japan was called an exiled disease, and its mortality rate was the highest in the world. GHQ / SCAP PHW Chief Crawford 
F. Sams (Brigadier General) wanted the Japanese pharmaceutical industry to be self-sufficient without using United States aid. From the first in 
1945, the U.S. military's intention to improve Japan's public health was to protect the health of its military personnel stationed in Japan and their 
families. Accepting the intention of PHW, the Japanese pharmaceutical industry used the SQC method that W. Edwards Deming introduced to 
Japan in 1950 for the production process of anti-TB drugs. The Japanese pharmaceutical industry drastically reduced the TB mortality rate by half 
in 1952 compared to 1947. The pharmaceutical industry contributed to the improvement of public health by domestically producing higher-quality 
anti-TB drugs in larger-volume. It provided those TB drugs to the Japanese market at lower prices. 
 




 Historical Background 
In 1945, public health in Japan was devastating. Notably, 
people called TB as a disease to ruin a national. The TB 
mortality rate was by far the highest in the world. GHQ/ 
SCAP/ PHW Chief Crawford F. Sams (Brigadier General) 
wanted the Japanese pharmaceutical industry to be self-
sufficient in 1945 to produce good quality healthcare products 
by itself without any distribution or aid from the United States 
not spending the US national budget. (Sams, 1949) However, 
the U.S. military intended to improve Japan's public health to 
protect the health of the military personnel of its own country, 
who stationed in Japan with their families at that time. 
With the intention of PHW, the Japanese pharmaceutical 
industry used the SQC method that Edwards Deming 
introduced in Japan in 1950 for the production process of anti-
TB drugs. The Japanese pharmaceutical industry reduced the 
TB mortality rate of people by half. It contributed to improving 
public health in occupied Japan by domestically producing 
high-quality anti-tuberculosis drugs in larger volume and 
providing them to the Japanese market at lower prices. 
This paper follows the themes of the paper issued in 
2019 analyzing the intentions of the Public Health and Welfare 
(PHW) of GHQ, (Sato, 2019) and the paper issued in 2020 
considering the reorganization of science and technology 
during Occupied Japan by GHQ/SCAP, (Sato, 2020) and 
developed the discussion in this paper. 
The SQC, a measure to mass-production of high-quality 
pharmaceutical products inexpensively, was an essential 
technique for PHW, Ministry of Health and Welfare (MHW), 
and the pharmaceutical industry in Japan to reduce the 
mortality rate, which was the most critical issue of public 
health in Japan at the time. 
The United States, which led the occupation, introduced 
the statistical quality control (SQC) having been used in the 
military field in the United States to the occupied Japan in 
1950 to promote Japanese economy. The Japanese 
pharmaceutical industry which accepted the intention of GHQ 
/ SCAP /PHW, wanted to promote its development. On the 
other hand, it desired to decrease the highest Japan's TB 
mortality rate in 1950. 
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Since 1951 when approaching the end of the occupation, 
the United States changed its policy toward Japan. It intended 
Japan to expand military production for the United States after 
its severe financial and monetary contraction policy of Dodge 
Line in 1949 and Korean War in 1950. (Sugita, 1999) 
Economic Science Section (ESS) of GHQ/SCAP 
appointed W. Edwards Deming to instruct the SQC to the 
Japanese pharmaceutical industry because ESS expected the 
pharmaceutical industry in Japan would produce a larger 
volume of higher-quality pharmaceutical products at a lower 
cost, and export them. 
 
2. Previous Studies 
First, this paper examines the previous research and 
tentatively answers the research question mentioned above.  
Sams wanted the pharmaceutical industry in Japan to 
manufacture a more significant volume of higher quality 
pharmaceutical products at a more moderate price to reduce 
the mortality rate. Then, for PHW, MHW (Ministry of Health 
and Welfare in Japan), and the pharmaceutical industry in 
Japan, the SQC, advocated by Deming, was the method to 
produce a larger volume of higher-quality pharmaceutical 
products at lower-cost. (Sato, 2019) 
SQC was one of the essential measures to reduce the 
mortality rate. For ESS, the SQC was the critical technique to 
lead Japan back to international society by exporting a large 
volume of high-quality products at low cost. (Sato, 2019) 
The reorganization of science and technology in 
Occupied Japan by GHQ, including the perspective of public 
health quality control included the intention to transform Japan 
into a supply base that conformed to global standards for the 
world. (Sato, 2020) 
Eiji Takemae states that the postwar healthcare reforms 
became one case of the most ideal implementation of human 
rights in the 20th century. (Takemae, 1986) Then, how were 
mortality and birth rates managed? According to One Hundred 
Years’ History of the Medical System, the Ministry of Health 
and Welfare (Former Ministry of Health, Labor and Welfare) 
prepared public health statistics. 
According to these statistics, until 1951 when the 
highest mortality rate changed from tuberculosis to brain 
hemorrhage, nearly 30 years since pneumonia or bronchitis 
changed from its first cause of death to the tuberculosis in 
Japan and the World in 1935. (Sams, 1949) 
(Koseishoimukyoku, 1976b) 
Mikio Watanabe studies postwar healthcare history 
focusing on the BCG Disputes, which was the controversy 
occurred in 1951 over compulsory BCG vaccination, the 
Immunization Act, which regulated vaccination to prevent the 
outbreak and spread of potentially infectious diseases from a 
public health perspective, adopted in 1946, and the TB Control 
Act, which was the law to prevent TB infection, establish 
necessary medical measures for TB patients, and prevent new 
TB infections, passed in 1951. (Watanabe, 2009a) 
Watanabe states that when reviewing the primary 
materials in Occupied Japan, he found a lot of historical facts 
that had predicted the occurrence of current health, medical 
care, and welfare problems. He insists that to study the 
establishment process of the legal system and its problems in 
the postwar period, solutions to such problems, and reception 
process of the people in Japan is required to solve the current 
comprehensive problems of health, medical care, and welfare.  
From the viewpoint of healthcare history, Watanabe 
does research in the BCG Disputes, which occurred in 1951 at 
the end of the occupation period when the Immunization Law, 
which was said to be the most powerful system in the world 
was enacted. Moreover, the Government entirely revised the 
TB Control Act against the tuberculosis, which had been called 
a national disease in Japan. Watanabe points out the 
chemotherapy including streptomycin, which was imported to 
Japan from the United States in 1949, contributed to large 
reduction in the TB mortality rate in Japan. He also says that 
the establishment of the TB Control Act was, however, delayed 
in 1951. He refers to the results of TB survey conducted after 
the Commemoration Ceremony of Fifty Percent Reduction of 
TB Mortality Rate held in May 1952 showed that the TB 
mortality rate decreased, though the tuberculosis infection still 
widely spread in Japan. (Watanabe, 2009b) 
As discussed in the BCG Disputes, BCG could neither 
prevent TB infection nor cure it. (Watanabe, 2009a) Therefore, 
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it was chemotherapy that contributed to the reduction in the 
tuberculosis mortality rate and the increase of efficacy for 
affected patients. 
Akihito Suzuki says that PHW made effort to reduce the 
incidence of TB and venereal disease because both diseases 
were serious impediments to improving standards of public 
health in Occupied Japan. According to Suzuki, although the 
TB was the leading cause of mortality among Japanese until 
1950, which had higher mortality rate than that of venereal 
disease, to protect the health of the American servicemen who 
consorted with Japanese prostitutes was more critical for PHW 
officials and Chief of PHW, Crawford F. Sams. Moreover, 
policies towards both TB and venereal disease did not emerge 
clearly until some years into the occupation, mainly because 
acute infectious diseases as smallpox, typhus and cholera were 
more urgent threats to public health in Occupied Japan. 
PHW at last started to address TB in 1947. Those 
circumstances were found in the statements provided by Sams 
to the Allied Council for Japan (ACJ) in 1947. PHW and the 
Ministry of Health and Welfare in Japan devoted more energy 
and resources to controlling TB and venereal diseases by 
measures, such as tuberculin, X-rays and blood tests, 
immunization with BCG, and diagnostic works in laboratories. 
Health centers worked to grasp the scale of problems and 
control them. (Aldous, 2012) 
Prominent previous studies have focused on the public 
sector. Then, how was the private sector working? This paper 
clarifies it. Specifically, this paper examines how the 
pharmaceutical industry contributed to public health. 
 
3. Domestic Production of Anti-TB Drugs 
This Chapter examines the domestic production of anti-
TB drugs in Japan, especially streptomycin and PAS.  
 
 Early History of TB and the Prevention 
Measures in Japan before 1945 
Before explaining the production of anti-TB drugs, this 
section should describe the history of TB. TB has a long 
history in Japan. The ancient Japanese medical book, “Ishinho” 
was written in 984. It describes the symptoms of pulmonary 
TB. In 1805, Japanese citizens already knew that TB was an 
infectious disease and contagious through the media of various 
clothes, utensils, and other things used by TB patients. In April 
1904, the Japanese government promulgated the first 
ordinances about the prevention of pulmonary TB. According 
to the regulation, the government provided spittoons in schools, 
factories, theaters, and other places designated by the local 
governors. Spitting other than in spittoons was prohibited. 
(U.S. Headquarters Army Service Forces, 1945)  
Private organizations, including the Japanese White 
Cross Society for preventing disease, started in 1911, and the 
Japanese Association for the Prevention of TB established its 
foundation in 1915. The first national sanitorium began its 
operation for pulmonary TB patients. The government granted 
the subsidy to cities of more than 300,000 inhabitants for 
establishing good sanatoria for TB treatment. (U.S. 
Headquarters Army Service Forces, 1945) 
The first TB statistical study started in 1899. From the 
statistical point of view, for the period 1915 to 1920, the 
average TB mortality rate was 231 of 100,000 people. The TB 
mortality rate was higher for females than it was for males. 
In the early 1930s, Japan began industrial development. 
The government had to provide proper measures to prevent TB 
or treat TB patients all over Japan. The government ordered to 
establish sanatoria in the Prefectures of Osaka, Hyogo, Gunma, 
Chiba, Tochigi, Mie, Aichi, Gifu Yamagata, Fukui, Ishikawa, 
Okayama, Yamaguchi, Oita, and Kumamoto.  
There were still many people who died in the above 
sanatoria. Japan needed to implement TB preventive measures 
or treatment to stop the high mortality rate. (U.S. Headquarters 
Army Service Forces, 1945) 
 
 TB Prevention Measures in Japan during World 
War II 
Japan Society for the Promotion of Science (JSPS) 
conducted joint research on BCG at the Tuberculosis 
Prevention Committee since September 1937. In 1943, the 
JSPS announced its research results. The Government of Japan 
expanded the scope of BCG vaccination from national school 
students to people provided under the National Physical 
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Fitness Law, including workers at factory establishments, 
students, pupils, and families of TB patients. The Government 
established the BCG vaccination manufacturing office in the 
TB Prevention Association. The national treasury subsidized 
the BCG vaccination fees of such people. The above measures 
led ten million people to receive the BCG vaccination in a year. 
In January 1944 Kekkaku Yobo Taisaku (Tuberculosis 
Prevention Measures) were decided in the Cabinet in Japan. 
(Koseishoimukyoku, 1976a) 
 
 TB Prevention Measures in Occupied Japan 
The government imported 200 grams of streptomycin 
for research activity in February 1949. Subsequently, in 
September 1949, the Cabinet decided on the outline for 
securing domestic production of streptomycin. The 
government allowed domestic production of streptomycin and 
PAS calcium in 1950. In the same year, the government 
covered streptomycin and PAS calcium for social insurance 
coverage. Since then, two anti-tuberculosis drugs have played 
a significant role in improving tuberculosis medicine. The TB 
mortality rate in Japan, however, was still in the highest 
position, namely 146.4 per 100,000 people, compared to other 
infectious disease mortality rates in 1950. (Koseishoimukyoku, 
1976a) 
 
 Production of Streptomycin 
Streptomycin started being imported in 1949, and 
chemotherapy of the drug helped reduce TB mortality rate. 
(Watanabe, 2009b) The medical cure with streptomycin started 
in 1949 when 200 and 400 kilograms of that anti-TB drug was 
first imported in March and the next in October. This volume 
of streptomycin was only 1% of 60,000 kilograms, which 
Japanese would have annually needed. (Aldous, 2012) Japan 
needed to manufacture anti-tuberculosis drug domestically. 
The above 600 kilograms of streptomycin were positioned to 
instruct its usage to Japanese physicians and to create demands 
for that anti-TB drug in Japan.  
GHQ/SCAP planned to create sufficient demands for 
streptomycin in Japan. GHQ/SCAP wanted Japanese 
manufacturers to produce streptomycin domestically and to 
commercialize such anti-TB drug in Japan. In the PHW Weekly 
Bulletin from October 14, 1945 to December 31, 1949 
reproduced by Satoshi Sugita, 200 kilograms and 400 
kilograms of streptomycin were distributed to the following 
pharmaceutical companies in Japan in July and October 
respectively, not to hospitals.  
In July, the weekly bulletin shows the following 
distribution list: 53,197 grams to Takeda Yakuhin Kogyo K.K. 
(Takeda Pharma), 50,000 grams to Shionogi Seiyaku K.K. 
(Shionogi Pharma), 41,195 grams to Sanyo K.K. (Sanyo 
Pharma), 32,396 grams to Yamanouchi Seiyaku K.K. 
(Yamanouchi Pharma), the remaining grams to Banyu Seiyaku 
K.K. (Banyu Pharma). (Sugita, 2008) 
In October, the weekly bulletin shows another 
distribution list as follows: 100,000 grams to Takeda 
Pharma,50,000 grams to Shionogi Pharma, 30,000 grams to 
Tanabe Pharma, 30,000 grams to Fujisawa Yakuhin Kogyo Co., 
Ltd. (Fujisawa Pharma), 30,000 grams to Yamanouchi Pharma, 
30,000 to Dainippon Seiyaku Co., Ltd.(Dainippon Pharma), 
30,000 grams to Daiichi Seiyaku Co., Ltd. (Daiichi Pharma), 
20,000 grams to Sankyo Pharma, 20,000 grams to Torii 
Seiyaku Co., Ltd.(Torii Pharma), 20,000 grams to Tokyo 
Tanabe Seiyaku Co., Ltd.(Tanabe Pharma, Tokyo), 20,000 
grams to Banyu Pharma and 20,000 grams to Nakamura Taki 
Shoten Co., Ltd.(Nakamura Taki Pharma). (Sugita, 2008) 
 
 Production of PAS 
Japanese private companies started domestic production 
of streptomycin in July 1950. In 1952, large factories in Japan 
succeeded in producing necessary volumes of streptomycin. 
They also produced PAS as anti-TB drug, which was said to 
assist streptomycin. Reduction percentage in TB mortality rate 
increased from 1951 to 1953. The number of people infected 
with tuberculosis, however, was still high. The rate of TB 
infection in 1961 was 445.9 / 100,000 population (0.445%), 
which was still high after 10 years later in Japan. Since the 
infection rate of venereal disease followed the same process. 
Akihito Suzuki calls such nature of diseases with this 
phenomenon as "entrenched nature of chronic infection 
disease." (Aldous, 2012) 
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According to the Japanese Society for History of 
Pharmacy (JSHP), Tanabe Pharma, which has the oldest 
history in Japan, obtained the approval by MHW to 
domestically manufacture and sell PAS as anti-TB drug in May 
1950. It was two months earlier the time when five Japanese 
companies including Meiji Seika obtained the approval to sell 
domestically produced streptomycin in July 1950. (Nihon 
Yakushi Gakkai, 1966) 
Pharmaceutical companies in Japan declined to 
manufacture streptomycin by themselves at first, however, 
since they did not afford a large amount of facility investment 
and high level of technology for fermentation equipment. In 
July 1950, Meiji Seika Kaisha, Limited (Meiji), Kyowahakko 
Kogyo Co., Ltd (Kyowa Hakko), Kaken Kagaku Co., Ltd. 
(Kaken Kagaku), Shimane Kagaku Co., Ltd. (Shimane 
Kagaku), Nihon Seibutsu Kenkyujo Co., Ltd. (Nihon Seibutsu 
Kenkyujo) obtained the approval to manufacture and sell 
streptomycin in Japan. Streptomycin, however, decreased its 
administration since it caused hearing loss as a side reaction. 
(Nihon Yakushi Gakkai, 1966) 
At the Headquarters of Tanabe Pharma in Osaka, after 
1948, researching staff began to read the latest American 
healthcare books stored in the GHQ Library, which was 
located in Osaka City. At that time, Ikuhisa Nakamura, who 
was a manager of the Documents Department of Tanabe 
Pharma, found a paper entitled "The Treatment of Tuberculosis 
in Sweden with para-aminosalicylic acid (PAS): A Review" 
published on a pharmaceutical journal, "The Lancet" in 1946 
by Swedish Scholar, Jorgen Lehmann. The chemical structure 
of PAS was similar to that of salicylic acid, which Tanabe 
Pharma had worked on salicylic acid for many years. Tanabe 
Pharma had imported salicylic acid from Germany since 1882 
and had sold that chemical as antiseptic agent. Further in 1897, 
Tanabe Pharma started to manufacture salicylic acid by itself. 
Therefore, researchers and engineers were accustomed to 
devising synthesis methods and characteristics. (Oda, 2001)  
Since August 1948, Tanabe Pharma, Tokyo had 
addressed in manufacturing PAS under the supervision of Dr. 
Shigehiko Sugasawa of Pharmaceutical Sciences, Tokyo 
University. Tanabe Pharma was successfully synthesized 500 
grams of PAS prototype. (Tanabe, 1983) Whereas 
streptomycin was a case of anti-TB drug managed by PHW, 
PAS was a case of anti-TB drug developed independently by 
Tanabe Pharma with a paper of Jorgen Lehmann who 
discovered that PAS was available oral administration. In 
addition, Tanabe Pharm received the permission from MHW 
on the paid distribution for clinical trials to doctors in 1949. 
(Oda, 2001) Tanabe Pharma started the sales of PAS with 
permission to manufacture PAS by itself in May 1950. By the 
end of 1950, 24 pharmaceutical companies participated in the 
PAS production in Japan. (GHQ, 1995) 
 
 Combined Treatment of Streptomycin and 
PAS 
The National Sanatoria History Study Group stated that 
in the first report of the Streptomycin Research Council 
conducted in November 1949, administration of streptomycin 
was intramuscularly injected twice a day of one gram in total 
per day and discontinued its administration up to 40 grams in 
total. The treatment was a short-term therapy. Mycobacterium 
tuberculosis decreased by about 50 percent. According to a 
survey after finishing the treatment, 25 percent of patients died. 
(Koseisho Imukyoku Kokuritsuryoyojokanai & 
Kokuritsuryoyojoshi Kenkyukai, 1976) 
Then, the experts found the combined treatment of 
streptomycin and PAS could prevent the streptomycin 
tolerance, and then, the healthcare physicians began the 
combined use of streptomycin and PAS for the TB treatment. 
(Shimao & Kekkakuyobokai, 2016) The Streptomycin 
Research Council began a combination therapy of 
streptomycin and PAS for the first time since January 1951. 
(Koseisho Imukyoku Kokuritsuryoyojokanai & 
Kokuritsuryoyojoshi Kenkyukai, 1976) 
 
 Who Controlled the Quality of Private Basis 
Pharmaceutical Products? 
Penicillin and streptomycin were manufactured by 
protection, technical guidance, and assistance of GHQ, but 
PAS was greatly different from the above drugs because the 
technology of PAS was introduced on a private basis. (Nihon 
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Yakushi Gakkai, 1966) The high reduction in TB mortality rate 
already started from 1950, before the Tuberculosis Control Act 
was enacted. As mentioned above, considering the BCG 
vaccination did not contribute to the reduction in TB mortality 
rate, the outcome of chemotherapy at that time should not be 
ignored. The time of commercialization and release of PAS 
was earlier than those of streptomycin by two months in Japan.  
The domestic manufacturing of PAS was approved in 
May 1950, and that of streptomycin was in July 1950. Three 
years after completion of the new facility of manufacturing 
streptomycin, the Meiji Seika received the grant of corporate 
tax exemption and was able to promote the project of 
manufacturing streptomycin. In addition, the government 
purchased manufactured streptomycin from July 18, 1950 to 
the end of 1951. (Meiji Seika Kabushiki Kaisha, 1987)  
According to GHQ, the total volume of manufactured 
streptomycin in 1950 reached 118,600 kilograms. On the other 
hand, the total volume of manufactured PAS increased from 
565 kilograms in January 1950 to 141,232 kilograms in total 
in 1950. (GHQ, 1995) 
In November 1948, about a year before the introduction 
of anti-TB streptomycin to Japan in 1949, the serious death 
accidents occurred caused by a biological drug. In Kyoto 
prefecture, out of 7642 vaccinated people in total, 606 people 
suffered from toxic poisoning and 68 people died after the 
diphtheria vaccination. In Shimane prefecture, 15 of 322 
vaccinated people died. In the Conference of Inspectors of 
Biological Preparations held on December 6, 1948, Sams 
strongly demanded the quality solution of pharmaceutical 
products by warning that the Preventive Vaccination Law in 
Japan was the best preventive vaccination law in the world, 
however, the death accidents of children caused by cheap and 
bad quality products manufactured by Japanese companies 
were disgraceful accidents for Japanese society. 
From the time of 1948 the PHW required the need for 
quality control in the pharmaceutical industry. (Watanabe, 
2009c) As mentioned in his book, Medic, Sams was 
particularly aware of importance of quality control and wanted 
Japanese pharmaceutical industry to be independent with 
establishment of high-quality standards and appropriate 
quantity of importing finished products. (Sams, 1998) 
 
4. Transition of TB Mortality Rate in Occupied 
Japan and the World 
To clarify the transition of TB mortality rate in Occupied 
Japan and the World, the chapter quotes the chart and the 
figure from the previous work of the Author as follows:  
 
Chart - 1 Transition of TB Mortality Rate in the World 
 
(Sato, 2014) 
(1): Percent decrease of TB mortality rate from 1946 to 1948  
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The reduction of Japanese TB mortality rate which is 
43.80 % from 1950 to 1952 is higher than that of other 
countries or other three-year periods. (See (1) and (2)) 
The highest reduction rate of TB mortality by 43.8% 
from 1950 to 1952 in Occupied Japan attributes to the 
following possible reasons:  
 
(i) To build public health center on a national basis.  
(Related to the public sector) 
(ii) To start school lunch system.  
(Related to the public sector) 
(iii) To start domestic production of anti-TB drugs. 
(Related to the private sector) 
 
About (i), the Government enacted the Public Health 
Center Law in 1947, accepting SCAPIN 48 which stipulates 
the public health in Japan. Then public health centers affected 
since 1947. The reduction of TB mortality rate is related to the 
period from 1947 to 1949, namely the reduction from 187.2 to 
168.9, which means 9.7% reduction. 
Next, considering (ii), the nationwide school lunch 
system started on February 1951. (Zenkokugakkokyushoku 
Rengokai, 2019) Then, the period on reduction of TB mortality 
rate is from 1951 to 1953 following the above. The reduction 
number of percentages is 39.7%. 
The third, as Chart 1 described (iii), domestic 
production of anti-TB drugs started in 1950. The reduction 
percentage of TB mortality rate is 43.8%. 
Considering the correlation of TB mortality rate and 
prevention movement against TB, the domestic production of 
anti-TB drugs has the highest percentage of correlation. 
 
5. Conclusion 
This paper aims to explore why occupied Japan was able 
to halve the tuberculosis (TB) mortality rate and improve 
public health.  
This paper followed the trends of the Japanese 
pharmaceutical industry, which produced higher-quality and 
larger-volume anti-TB drugs at a lower cost, with the intention 
of the Public Health Welfare Section (PHW) of General 
Headquarters Supreme Commander for the Allied Powers 
(GHQ/SCAP). 
The Japanese pharmaceutical industry, especially 
pharmaceutical companies, by accepting the intention of 
GHQ/SCAP, made efforts to improve public health using 
statistical quality control method instructed by W, Edwards 
Deming during the occupation period.  
The critical points of contribution of pharmaceutical 
companies contributed to Japanese public health in Occupied 
Japan are as follows: 
 
(i) Domestic production of larger volume of higher 
quality anti-TB drugs at lower prices  
(ii) Drastic reduction of high TB mortality rate during 
the period from 1950 to 1952 
 
The Japanese pharmaceutical companies obtained the 
approval to domestically manufacture anti-TB drugs including 
streptomycin and PAS since 1950. They have been combined 
to dose the TB patients since 1951.    
Furthermore, thanks to the SQC method advocated by 
Deming, the larger volume of high-quality anti-TB drugs at 
lower cost came on to the market. These anti-TB drugs met the 
SQC method which was considered as international standards 
in Occupied Japan. The Japanese Pharmaceutical industry in 
Occupied Japan realized the GHQ expectation to produce 
high-quality pharmaceutical products and reduce high TB 
mortality rate. Such a large volume of high-quality 
pharmaceutical products at lower cost connected to lead Japan 
back to international society. 
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